Gilead Sciences, Inc. or Walgreens Boots Alliance, Inc.: Who Manages SG&A Costs Better?

Gilead vs. Walgreens: SG&A Cost Management Showdown

__timestampGilead Sciences, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 2014298300000017691000000
Thursday, January 1, 2015342600000021669000000
Friday, January 1, 2016339800000023425000000
Sunday, January 1, 2017387800000023618000000
Monday, January 1, 2018405600000024638000000
Tuesday, January 1, 2019438100000023183000000
Wednesday, January 1, 2020515100000022836000000
Friday, January 1, 2021524600000023798000000
Saturday, January 1, 2022567300000024994000000
Sunday, January 1, 2023609000000025479000000
Monday, January 1, 202428113000000
Loading chart...

Infusing magic into the data realm

Managing SG&A Costs: A Tale of Two Giants

In the competitive landscape of the pharmaceutical and retail sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Gilead Sciences, Inc. and Walgreens Boots Alliance, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, Gilead Sciences saw a steady increase in SG&A expenses, rising by approximately 104% from $3 billion to $6 billion. In contrast, Walgreens Boots Alliance maintained a more consistent trajectory, with expenses fluctuating around $23 billion to $25 billion, peaking at $28 billion in 2024. This suggests that while Gilead is expanding its operational scope, Walgreens is focusing on efficiency. The data highlights the importance of strategic cost management in sustaining competitive advantage and profitability in their respective industries.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025